Comparison of carvedilol vs. bisoprolol for heart failure with reduced ejection fraction (HFrEF): A systematic review and meta-analysis from the Asian population
China, Indonesia, and Malaysia have the highest age-standardized rates of heart failure in Asia, according to the Global Burden of Disease study. While numerous systematic reviews and meta-analyses have compared bisoprolol and carvedilol in HFrEF, most have focused on Western populations. To address...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Pensoft Publishers
2025-01-01
|
| Series: | Pharmacia |
| Online Access: | https://pharmacia.pensoft.net/article/142130/download/pdf/ |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832582813280370688 |
|---|---|
| author | Yedy Purwandi Sukmawan Tita Nofianti Anisa Pebiansyah |
| author_facet | Yedy Purwandi Sukmawan Tita Nofianti Anisa Pebiansyah |
| author_sort | Yedy Purwandi Sukmawan |
| collection | DOAJ |
| description | China, Indonesia, and Malaysia have the highest age-standardized rates of heart failure in Asia, according to the Global Burden of Disease study. While numerous systematic reviews and meta-analyses have compared bisoprolol and carvedilol in HFrEF, most have focused on Western populations. To address this gap, we conducted a meta-analysis of RCTs and cohort studies involving Asian patients with HFrEF from PubMed and Cochrane databases that reported all-cause mortality, hospital admission, and left ventricular ejection fraction (LVEF) increase. The search result identified five eligible studies, primarily from Taiwan, Japan, and South Korea, with a total of 11,577 participants. The meta-analysis revealed no significant difference between bisoprolol and carvedilol in terms of all-cause mortality (RR 1.04, p 0.62, I2 = 0%), hospitalization (RR 1.23, p. 0.23, I2 = 0%), and LVEF increase (RR -1.40, p. 0.50, I2 = 0%). These findings suggest that both drugs have comparable efficacy in the Asian population. |
| format | Article |
| id | doaj-art-611ddfc6c5754bcda7569466ad67058a |
| institution | Kabale University |
| issn | 2603-557X |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Pensoft Publishers |
| record_format | Article |
| series | Pharmacia |
| spelling | doaj-art-611ddfc6c5754bcda7569466ad67058a2025-01-29T08:30:51ZengPensoft PublishersPharmacia2603-557X2025-01-01721810.3897/pharmacia.72.e142130142130Comparison of carvedilol vs. bisoprolol for heart failure with reduced ejection fraction (HFrEF): A systematic review and meta-analysis from the Asian populationYedy Purwandi Sukmawan0Tita Nofianti1Anisa Pebiansyah2University of Bakti Tunas HusadaUniversity of Bakti Tunas HusadaUniversity of Bakti Tunas HusadaChina, Indonesia, and Malaysia have the highest age-standardized rates of heart failure in Asia, according to the Global Burden of Disease study. While numerous systematic reviews and meta-analyses have compared bisoprolol and carvedilol in HFrEF, most have focused on Western populations. To address this gap, we conducted a meta-analysis of RCTs and cohort studies involving Asian patients with HFrEF from PubMed and Cochrane databases that reported all-cause mortality, hospital admission, and left ventricular ejection fraction (LVEF) increase. The search result identified five eligible studies, primarily from Taiwan, Japan, and South Korea, with a total of 11,577 participants. The meta-analysis revealed no significant difference between bisoprolol and carvedilol in terms of all-cause mortality (RR 1.04, p 0.62, I2 = 0%), hospitalization (RR 1.23, p. 0.23, I2 = 0%), and LVEF increase (RR -1.40, p. 0.50, I2 = 0%). These findings suggest that both drugs have comparable efficacy in the Asian population.https://pharmacia.pensoft.net/article/142130/download/pdf/ |
| spellingShingle | Yedy Purwandi Sukmawan Tita Nofianti Anisa Pebiansyah Comparison of carvedilol vs. bisoprolol for heart failure with reduced ejection fraction (HFrEF): A systematic review and meta-analysis from the Asian population Pharmacia |
| title | Comparison of carvedilol vs. bisoprolol for heart failure with reduced ejection fraction (HFrEF): A systematic review and meta-analysis from the Asian population |
| title_full | Comparison of carvedilol vs. bisoprolol for heart failure with reduced ejection fraction (HFrEF): A systematic review and meta-analysis from the Asian population |
| title_fullStr | Comparison of carvedilol vs. bisoprolol for heart failure with reduced ejection fraction (HFrEF): A systematic review and meta-analysis from the Asian population |
| title_full_unstemmed | Comparison of carvedilol vs. bisoprolol for heart failure with reduced ejection fraction (HFrEF): A systematic review and meta-analysis from the Asian population |
| title_short | Comparison of carvedilol vs. bisoprolol for heart failure with reduced ejection fraction (HFrEF): A systematic review and meta-analysis from the Asian population |
| title_sort | comparison of carvedilol vs bisoprolol for heart failure with reduced ejection fraction hfref a systematic review and meta analysis from the asian population |
| url | https://pharmacia.pensoft.net/article/142130/download/pdf/ |
| work_keys_str_mv | AT yedypurwandisukmawan comparisonofcarvedilolvsbisoprololforheartfailurewithreducedejectionfractionhfrefasystematicreviewandmetaanalysisfromtheasianpopulation AT titanofianti comparisonofcarvedilolvsbisoprololforheartfailurewithreducedejectionfractionhfrefasystematicreviewandmetaanalysisfromtheasianpopulation AT anisapebiansyah comparisonofcarvedilolvsbisoprololforheartfailurewithreducedejectionfractionhfrefasystematicreviewandmetaanalysisfromtheasianpopulation |